Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 1,231,542 |
|
|||||
| News | (1) | ||||||
| Day High | 52.2175 | Low High |
|||||
| Day Low | 51.39 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Incyte Corporation | INCY | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.06 | 0.12% | 51.98 | 13:54:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 52.00 | 51.39 | 52.2175 | 51.92 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 24,221 | 1,231,542 | US$ 51.82 | US$ 63,812,408 | - | 50.27 - 75.74 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 13:54:06 | 9 | US$ 51.98 | USD |
Incyte (INCY) Options Flow Summary
Incyte Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 11.68B | 224.53M | - | 3.7B | 597.6M | 2.66 | 19.54 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Incyte News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INCY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 53.51 | 54.09 | 51.39 | 52.58 | 1,908,571 | -1.53 | -2.86% |
| 1 Month | 57.53 | 57.555 | 51.39 | 54.62 | 1,651,008 | -5.55 | -9.65% |
| 3 Months | 60.50 | 61.865 | 51.39 | 57.55 | 1,764,274 | -8.52 | -14.08% |
| 6 Months | 55.16 | 67.365 | 50.27 | 58.07 | 1,821,167 | -3.18 | -5.77% |
| 1 Year | 74.56 | 75.74 | 50.27 | 60.46 | 1,798,819 | -22.58 | -30.28% |
| 3 Years | 84.60 | 88.26 | 50.27 | 69.58 | 1,640,515 | -32.62 | -38.56% |
| 5 Years | 73.71 | 111.05 | 50.27 | 75.29 | 1,511,971 | -21.73 | -29.48% |
Incyte Description
| Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
